Halozyme Therapeutics Inc (HALO)vsBeiGene, Ltd. (ONC)
HALO
Halozyme Therapeutics Inc
$63.24
+1.93%
HEALTHCARE · Cap: $7.32B
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 283% more annual revenue ($5.34B vs $1.40B). HALO leads profitability with a 22.7% profit margin vs 5.4%. HALO trades at a lower P/E of 24.2x. HALO earns a higher WallStSmart Score of 70/100 (B).
HALO
Strong Buy70
out of 100
Grade: B
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+33.6%
Fair Value
$119.81
Current Price
$63.24
$56.57 discount
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 56.3%
Revenue surging 51.6% year-over-year
Keeps 23 of every $100 in revenue as profit
Earnings expanding 36.2% YoY
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
ROE of 1.5% — below average capital efficiency
Trading at 154.2x book value
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : HALO
The strongest argument for HALO centers on Operating Margin, Revenue Growth, Profit Margin. Profitability is solid with margins at 22.7% and operating margin at 56.3%. Revenue growth of 51.6% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : HALO
The primary concerns for HALO are Return on Equity, Price/Book.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
HALO profiles as a growth stock while ONC is a hypergrowth play — different risk/reward profiles.
HALO carries more volatility with a beta of 1.02 — expect wider price swings.
HALO is growing revenue faster at 51.6% — sustainability is the question.
HALO generates stronger free cash flow (218M), providing more financial flexibility.
Bottom Line
HALO scores higher overall (70/100 vs 42/100), backed by strong 22.7% margins and 51.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?